SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Concord Biotech gets EIR from USFDA for API facility at Dholka

24 Jun 2025 Evaluate

Concord Biotech has received an establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at its API facility at Dholka. The said inspection was conducted from April 28, 2025 till May 02, 2025. The USFDA has officially concluded its inspection. This closure indicates that no regulatory action is required, and the facility is permitted to continue its operations without any restrictions.

Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology.

Concord Biotech Share Price

1068.45 1.05 (0.10%)
21-Apr-2026 09:42 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1672.45
Dr. Reddys Lab 1223.60
Cipla 1230.40
Zydus Lifesciences 929.00
Lupin 2331.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×